Myovant Sciences Ltd (MYOV) Stock Price, Quote, News and Overview
NYSE:MYOV - New York Stock Exchange, Inc. - BMG637AM1024 - Common Stock - Currency: USD
MYOV Quote, Performance and Key Statistics
26.98
-0.01 (-0.04%)
The current stock price of MYOV is 26.98 USD. In the past month the price increased by 0.33%. In the past year, price increased by 125.4%.
MYOV Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About MYOV
Company Profile
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. The firm is focused on redefining care for women and for men through science, medicines and transformative advocacy. The Company’s two products include ORGOVYX (relugolix 120 mg), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer; and MYFEMBREE, a once-daily oral treatment for the management of heavy menstrual bleeding associated with uterine fibroids. The Company, through its subsidiary, Myovant Sciences GmbH develops supplemental New Drug Application for once-daily MYFEMBREE for the management of moderate to severe pain associated with endometriosis and being assessed for contraceptive efficacy in women ages 18-35 years who are at risk for pregnancy. The company develops Relugolix for the treatment of men with advanced prostate cancer. The firm is also developing MVT-602, which has completed a Phase IIa study for the treatment of female infertility.
Company Info
Myovant Sciences Ltd
Ste 1 3rd Fl, 11/12 St. James's Square
London SW1Y 4LB GB
CEO: David Marek
Employees: 579
Company Website: http://myovant.com/
Phone: 442074003351.0
Myovant Sciences Ltd / MYOV FAQ
What is the stock price of Myovant Sciences Ltd today?
The current stock price of MYOV is 26.98 USD. The price decreased by -0.04% in the last trading session.
What is the ticker symbol for Myovant Sciences Ltd stock?
The exchange symbol of Myovant Sciences Ltd is MYOV and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is MYOV stock listed?
MYOV stock is listed on the New York Stock Exchange, Inc. exchange.
What is the price forecast or stock price prediction for Myovant Sciences Ltd stock?
10 analysts have analysed MYOV and the average price target is 27.54 USD. This implies a price increase of 2.08% is expected in the next year compared to the current price of 26.98. Check the Myovant Sciences Ltd stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is Myovant Sciences Ltd worth?
Myovant Sciences Ltd (MYOV) has a market capitalization of 2.62B USD. This makes MYOV a Mid Cap stock.
How many employees does Myovant Sciences Ltd have?
Myovant Sciences Ltd (MYOV) currently has 579 employees.
What are the support and resistance levels for Myovant Sciences Ltd (MYOV) stock?
Myovant Sciences Ltd (MYOV) has a support level at 26.96 and a resistance level at 26.99. Check the full technical report for a detailed analysis of MYOV support and resistance levels.
Is Myovant Sciences Ltd (MYOV) expected to grow?
The Revenue of Myovant Sciences Ltd (MYOV) is expected to grow by 81.1% in the next year. Check the estimates tab for more information on the MYOV EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy Myovant Sciences Ltd (MYOV) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MYOV, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MYOV, evaluating the profitability, health, valuation and growth aspects
- Myovant Sciences Ltd (MYOV) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Myovant Sciences Ltd (MYOV) Sales and EPS estimates to see what analysts future expectations are.
- Myovant Sciences Ltd (MYOV) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Myovant Sciences Ltd (MYOV) Insider and Institutional Ownership to learn about the owners and their transactions.
- Myovant Sciences Ltd (MYOV) Stock Chart to make your own analysis
- Myovant Sciences Ltd (MYOV) Latest news and press-releases to stay up to date.
Does Myovant Sciences Ltd (MYOV) stock pay dividends?
MYOV does not pay a dividend.
When does Myovant Sciences Ltd (MYOV) report earnings?
Myovant Sciences Ltd (MYOV) will report earnings on 2023-05-08, after the market close.
What is the Price/Earnings (PE) ratio of Myovant Sciences Ltd (MYOV)?
Myovant Sciences Ltd (MYOV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.91).
MYOV Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to MYOV. When comparing the yearly performance of all stocks, MYOV is one of the better performing stocks in the market, outperforming 98.07% of all stocks.
MYOV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MYOV. MYOV has a bad profitability rating. Also its financial health evaluation is rather negative.
MYOV Financial Highlights
Over the last trailing twelve months MYOV reported a non-GAAP Earnings per Share(EPS) of -1.91. The EPS increased by 22.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MYOV Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 76% to MYOV. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 19.42% and a revenue growth 81.1% for MYOV